Non Small Cell Lung Cancer
Conditions
Brief summary
This is a multi-center, randomized, double-blind, phase III study to evaluate the efficacy and safety of CS1001 in combination with platinum-containing chemotherapy versus placebo in combination with chemotherapy in first-line treatment-naive subjects with stage IV non-small cell lung cancer (NSCLC).
Interventions
BIOLOGICALCS1001 monoclonal antibody
Participant will receive CS1001 monoclonal antibody 1200 mg by intravenous infusion every 3 weeks, for up to 24 months; Drug Carboplatin on Day 1 of each 21-day cycle; Drug Pemetrexed on Day 1 of each 21-day cycle; Drug Paclitaxel on Day 1 of each 21-day cycle
BIOLOGICALCS1001 placebo
Participant will receive CS1001 placebo 1200 mg by intravenous infusion every 3 weeks, for up to 24 months; Drug Carboplatin on Day 1 of each 21-day cycle; Drug Pemetrexed on Day 1 of each 21-day cycle; Drug Paclitaxel on Day 1 of each 21-day cycle
Sponsors
CStone Pharmaceuticals
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
1. Willing to participate in this trial; fully understand and informed of this trial, and able to provide written informed consent form (ICF). 2. 18-75 years of age (18 and 75 included) on the day of signing ICF. 3. Histologically or cytologically confirmed stage IV non-small cell lung cancer (staged according to the 8th International Association for the Study of Lung Cancer (IASLC) classification. 4. Subjects haven't received systemic treatment for advanced/metastatic NSCLC. 5. Measurable target lesion evaluated by investigators according to RECIST v1.1. 6. ECOG PS of 0-1. 7. Life expectancy ≥ 12 weeks. 8. Subject with prior anti-cancer treatment can only be enrolled when all toxicities except for hearing loss, alopecia and fatigue, of prior anti-cancer treatment has recovered to ≤ Grade 1 according to National Cancer Institute \[NCI\] Common Terminology Criteria for Adverse Events (CTCAE) v4.03. 9. Subjects must have adequate organ function. 10. Women of childbearing potential (WOBPC, as defined in section 13.5) must have a negative pregnancy test ≤7 days prior to the first dose of investigational product. WOBCP or fertile men and their WOBCP partners must agree to use an effective method of birth control from providing signed ICF and for 6 months after last dose of investigational product.
Exclusion criteria
1. Histologically confirmed small cell lung cancer or containing small cell component. 2. Subjects with current active autoimmune disease or prior history of autoimmune disease. 3. Malignancies other than NSCLC within 5 years prior to randomization. 4. Known history of human immunodefiency virus (HIV) infection and/or acquired immune deficiency syndrome. 5. Subject with active hepatitis B or hepatitis C. 6. Subjects with known history of alcoholism or drugs abuse. 7. Has a known hypersensitivity to any component of study treatment, for example pemetrexed, cisplatin, carboplatin or other platinum compounds. 8. Subjects with other conditions that in the investigator's opinion may influence subject's compliance or make subjects not suitable for participating in this trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Progression-free survival (PFS) in all subjects evaluated by investigators according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 | up to approximately 5 years |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Objective Response Rate (ORR) assessed by the investigator according to RECIST v1.1 | up to approximately 5 years | ORR, defined as the proportion of patients with a complete response (CR) or partial response (PR) on two consecutive occasions \>=4 weeks apart, as determined by the investigator according to RECIST v1.1. |
| Duration of response (DOR) assessed by the investigator according to RECIST v1.1 | up to approximately 5 years | DOR defined as the time between the date of the earliest qualifying response and the date of progressive disease or all-cause death, whichever occurs first, as determined by the investigator according to RECIST v1.1. |
| Safety and tolerability of CS1001 or placebo in combination with platinum-based chemotherapy | up to approximately 5 years | — |
| Pharmacokinetics (PK) and immunogenecity of CS1001 | up to approximately 5 years | — |
| Efficacy of CS1001 monotherapy in subjects cross over to receive CS1001 who experienced progressive disease after assigned to the placebo group in the double-blind phase (CS1001 or placebo in combination with chemotherapy) | up to approximately 5 years | — |
| Overall Survival (OS) | up to approximately 7 years | OS defined as the time from randomization to all-cause death. |
| PFS in subgroup of participants with PD-L1 Expression≥1%, as determined by the investigator | up to approximately 5 years | PFS after randomization as determined by the investigator according to RECIST v1.1 in the subgroup of patients with PD-L1 expression ≥1% defined by the SP263 immunohistochemistry (IHC) assay. |
| PFS assessed by BICR | up to approximately 5 years | PFS defined as the time from randomization to the first occurrence of disease progression or all-cause death (whichever occurs first), as determined by the BICR according to RECIST v1.1 |
Countries
China
Outcome results
None listed